Precipio Stock Earnings Reports

Precipio reported 2025 results showing material progress toward financial stability and growth. Key points: revenue was $24M, up 30% year-over-year; the company achieved positive cash flow in 2025 and repaid the Change Healthcare loan, exercised remaining warrants and moved to a cleaner balance sheet. Gross margin improved to 45% (from 41% in 2024) driven by Pathology Services scale; Product division margins were 30% in Q3 but jumped to 90% in Q4 due to a concentrated production run intended to build inventory for anticipated downtime. Pathology Services remains the cash-generating backbone with unused lab capacity, enabling operational leverage and faster margin improvement as volumes grow. Product revenues underperformed in 2025 because of customer operational interruptions and an undersized commercial team; management has since hired a Chief Commercial Officer and two experienced business development hires (January 2026) to accelerate product sales and distribution. The company emphasized improved customer onboarding, distributor relationships, expanded manufacturing capacity, academic validation (Memorial Sloan Kettering and Wayne State collaborations), and a pipeline of labs progressing through validation. Management plans to prioritize growing the Products division in 2026—targeting adoption of HemeScreen and Bloodhound products, converting the pipeline to recurring revenues, and launching differentiated services (e.g., next-day AML molecular testing followed by a comprehensive 5-day result). Management estimates an approximately $500M U.S. addressable market for their products and expects the revenue mix to shift from ~90/10 (pathology/products) toward a more balanced split over 3–5 years. Overall, the company moved from capital preservation to deploying resources for growth while retaining operational discipline.